Supportive Care in Low-Risk Myelodysplastic Syndromes: Role of Erythropoiesis Stimulating Agents (ESAs)

被引：0
|
作者：
Cerchione, Claudio [1 ]
Alfinito, Fiorella [2 ]
Giannini, Benedetta Maria [1 ]
Pane, Fabrizio [2 ]
Musuraca, Gerardo [1 ]
Martinelli, Giovanni [1 ]
机构：
[1] IRCCS, Hematol Unit, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, FC, Italy
[2] AOU Federico II, Naples, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
MDS; myelodysplastic syndromes; ESAS; supportive; care; erythropoietin;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-502
引用
收藏
页码：S318 / S318
页数：1
相关论文
共 50 条
  • [1] Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes
    Cerchione, Claudio
    Alfinito, Fiorella
    Soriente, Ilaria
    D'Arco, Alfonso Maria
    Danise, Paolo
    Cerciello, Giuseppe
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S325
  • [2] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Castelli, Roberto
    Schiavon, Riccardo
    Rossi, Valentina
    Deliliers, Giorgio Lambertenghi
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [3] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Roberto Castelli
    Riccardo Schiavon
    Valentina Rossi
    Giorgio Lambertenghi Deliliers
    Medical Oncology, 2018, 35
  • [4] Erythropoiesis stimulating agents and other growth factors in low-risk MDS
    Hellstrom-Lindberg, Eva p
    van de Loosdrecht, Arjan
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) : 401 - 410
  • [5] Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
    Steensma, David P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (01) : 3 - 5
  • [6] Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
    Kosmider, Olivier
    Passet, Marie
    Santini, Valeria
    Platzbecker, Uwe
    Andrieu, Valerie
    Zini, Gina
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Masala, Erico
    Balleari, Enrico
    Bulycheva, Ekaterina
    Dreyfus, Francois
    Fenaux, Pierre
    Fontenay, Michaela
    Park, Sophie
    HAEMATOLOGICA, 2016, 101 (07) : 280 - 283
  • [7] Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
    Smith, Sheila Weiss
    Sato, Masayo
    Gore, Steven D.
    Baer, Maria R.
    Ke, Xuehua
    McNally, Diane
    Davidoff, Amy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (01): : 15 - 20
  • [8] Amifostine in the treatment of low-risk myelodysplastic syndromes
    Grossi, A
    Fabbri, A
    Santini, V
    Leoni, F
    Nozzoli, C
    Longo, G
    Pagliai, G
    Ciolli, S
    Ferrini, PR
    HAEMATOLOGICA, 2000, 85 (04) : 367 - 371
  • [9] rHuEpo treatment in low-risk myelodysplastic syndromes
    Grossi, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 574 - 574
  • [10] Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
    Itzykson, R.
    Thepot, S.
    Beyne-Rauzy, O.
    Ame, S.
    Isnard, F.
    Dreyfus, F.
    Salanoubat, C.
    Taksin, A. L.
    Chelgoum, Y.
    Berthon, C.
    Malfuson, J. V.
    Legros, L.
    Vey, N.
    Turlure, P.
    Gardin, C.
    Boehrer, S.
    Ades, L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 397 - 400
12345